



CareSource considers Takhzyro (Ivanadolumab -flyo) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off -Label policy.

DATE	ACTION/DESCRIPTION
08/06/2019	New policy Takhzyro created.
01/13/2021	Updated criteria to align with the other HAE prophylactic drug revisions. Updated references. Greatly simplified the diagnostic confirmation criteria. Removed minimum required number of attacks, per guidelines; will just ask for baseline measure. Removed the statement about causative medications. Added that they must try on-demand treatment first. Rewrote the renewal criteria and removed log book